TELA Bio(US:TELA) Globenewswireยท2025-11-13 21:01Core Insights - TELA Bio, Inc. reported a 9% increase in revenue for Q3 2025, reaching $20.7 million compared to Q3 2024, driven by new customers and international sales [3][9] - The company aims for at least 16% revenue growth for the full year 2025 compared to 2024 [7][9] - TELA Bio has strengthened its capital position with a new credit facility of up to $70 million from Perceptive Advisors [8][9] Financial Highlights - Gross profit for Q3 2025 was $14.0 million, representing 67.5% of revenue, slightly down from 67.8% in Q3 2024 [4] - Operating expenses decreased to $21.5 million in Q3 2025 from $22.2 million in Q3 2024, attributed to lower compensation and benefits [5] - The loss from operations improved to $7.6 million in Q3 2025 from $9.4 million in Q3 2024, while the net loss decreased to $8.6 million from $10.4 million [6] Strategic Developments - The leadership team has been strengthened, and strategic changes have been made to enhance the commercial organization [2][3] - The company is focusing on building a patient-centric, performance-driven culture to support growth [3] - TELA Bio has expanded its Board with new appointments to enhance capabilities [9]